Novavax (NVAX) Notes Payables (2010 - 2022)

Novavax's (NVAX) quarterly Notes Payables came in at $324.9 million in Q4 2022, little changed quarter-over-quarter from $324.5 million in Q3 2022.

Novavax (NVAX) Notes Payables (2010 - 2022) Analysis & Trends

Novavax's Notes Payables history runs 8 years deep, the most recent figure standing at $324.9 million for Q4 2022.

On a quarterly basis, Notes Payables changed N/A year-over-year to $324.9 million in Q4 2022; TTM through Dec 2022 was $324.9 million, a N/A change from a year earlier, with the FY2022 full-year figure at $324.9 million, changed N/A from the prior year.
Notes Payables was little changed at $324.9 million in Q4 2022 per NVAX's latest filing, from $324.5 million in the prior quarter.
Across five years, Notes Payables topped out at $324.9 million in Q4 2022 and bottomed at $323.8 million in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Novavax	788.01 Mn	-2.33 Mn	108.82 Mn

Download Data